Identifying Liver Toxicity Markers from Drug Studies
Author Information
Author(s): Chang Ching-Wei, Beland Frederick A., Hines Wade M., Fuscoe James C., Han Tao, Chen James J.
Primary Institution: National Center for Toxicological Research, FDA
Hypothesis
There exist biochemical signals in liver or body fluids that can distinguish between drug candidates that may cause liver injury and those that do not.
Conclusion
The study identified potential genomic biomarkers for liver toxicity that could help predict drug-induced liver injury in susceptible patients.
Supporting Evidence
- Six hundred and ninety-five genes and 61 pathways were selected based on the classification scheme.
- Two of the 12 animals in the tolcapone group were found to have high ALT, AST, or TBIL levels.
- The gene Vars2 was identified in both animals and is related to liver toxicity.
Takeaway
Researchers studied two drugs to find out how they affect the liver and discovered some genes that can help tell if a drug might be harmful to the liver.
Methodology
The study involved a 28-day oral toxicity study in male Sprague-Dawley rats, analyzing liver and plasma samples for gene expression and clinical chemistry.
Potential Biases
Potential bias due to the small sample size and the specific strain of rats used.
Limitations
The study focused on a small number of animals, which may not represent the broader population's response to the drugs.
Participant Demographics
Male Sprague-Dawley rats, aged six weeks.
Statistical Information
P-Value
0.011, 0.026, 0.044, 0.048
Statistical Significance
p<0.05
Digital Object Identifier (DOI)
Want to read the original?
Access the complete publication on the publisher's website